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Autosomal dominant polycystic kidney disease
(ADPKD) is a common Mendelian disorder. Linkage stud-
ies have estimated that 80 to 85% of cases of ADPKD are
due to PKD1 mutations, while most of the remaining cases
are due to PKD2 mutations [1]. In the past three years, five
pedigrees with ADPKD have been reported to be unlinked
to both of these genes. These families have different
geographic origins: Canada [2], Portugal [3], Bulgaria [4],
Italy [5], and Spain [6], and have led to the suggestion of at
least one additional gene for ADPKD (PKD3). While the
presence of an as yet unmapped disease gene can explain
the absence of linkage in these families to the known genes
for ADPKD, the converse may not be true. In this com-
mentary, we shall consider the potential confounders that
could lead to false exclusion of these putative “PKD3”
families from linkage to the known genes. Excluding these
confounders are crucial to ensure that the unlinked families
are indeed due to mutations in a novel gene. Otherwise, a
genome-wide search for PKD3 may be premature.
The common confounders that may lead to false exclu-
sion of linkage to the known genes include: (1) genotyping
error; (2) DNA sample mix-up; (3) non-paternity; and (4)
misdiagnosis (including phenocopies and non-penetrance).
In general, the presence of any of the first three confound-
ers is suggested by finding inconsistencies in the segrega-
tion of marker alleles from parents to children, excessive
number of inter-marker recombinants over a known ge-
netic interval, or double-recombinants between close mark-
ers. Indeed, careful inspection of the PKD1 haplotypes in
the Portugese PKD3 family reveals four inter-marker re-
combinants in III:37 between the markers 39HVR and SM7
(Fig. 1) [3]. Over the 9.0 cM interval flanked by 39HVR and
SM7, only approximately one inter-marker recombinant is
expected for every 10 chromosomes genotyped. Thus, the
presence of four inter-marker recombinants in this region
in a single chromosome is highly unlikely to be due to
chance, and suggests the possibility of genotyping errors, or
DNA sample mix-up. Of the remaining four families,
genotype data are available in three. In the Italian family,
five members were available and only two PKD2 markers
were genotyped [5]. In the Spanish family, seven members
were available and only two PKD1 markers were genotyped
[6]. Because only a few individuals and markers were
genotyped, it would be difficult to detect the presence of
the above confounders in these families. Typing additional
markers flanking the known disease genes should help to
confirm these findings. With respect to misdiagnosis, both
false positive and negative diagnoses can lead to apparent
exclusion of linkage from the known genes for ADPKD.
While the ultrasonographic diagnostic criteria for cystic
disease due to PKD1 mutations have been well established
[7, 8], the diagnostic criteria for the milder disease associ-
ated with PKD2 mutations have not [8]. Thus, for an at-risk
individual, cystic disease due to PKD1 mutations is assumed
to be fully penetrant by age 30 and a negative ultrasound at
this age essentially rules out the disease [7, 8]. However,
using the same criterion for cystic disease due to PKD2
mutations may potentially lead to a false negative diagno-
sis. The issue of age-dependent penetrance for disease due
to PKD2 mutations may be relevant for the Italian PKD3
family since the basis for suggesting that it is unlinked to
the known genes is hinged upon only one member (II:3).
This individual was scored as a double recombinant at the
PKD2 locus because of the absence of cysts on ultrasound
at age 32 [5].
In addition to the potential confounders noted above,
bilineal transmission of two independent PKD mutations
within the same family may also lead to false exclusion of
linkage when only one disease locus is considered at a time.
Two scenarios may exist: firstly, mutations involving both
copies of either PKD1 or PKD2 may be segregating within
the same family. In this case, individuals carrying two
identical mutations are termed homozygotes, whereas
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those carrying two different mutant alleles are termed
compound heterozygotes. Alternatively, one PKD1 and one
PKD2 mutations may be segregating within the same
family. Individuals simultaneously affected by mutations in
two different genes that cause the same disease are said to
have digenic mutations. Haplotype analysis of PKD1-linked
pedigrees as well as recent mutation studies of PKD1 and
PKD2 have shown that identical mutations in apparently
unrelated families are uncommon [9–11]. In Caucasian
populations, ADPKD from mutations in PKD1 and PKD2
is estimated to occur in ;1/103 and ;1/104 live births,
respectively [1]. Under the assumption of random mating,
one would therefore expect to find bilineal disease with two
PKD1 mutations within a family in ;1/106 marriages, with
both a PKD1 and PKD2 mutations in ;1/107 marriages, and
with two PKD2 mutations in ;1/108 marriages. While
expected to be rare, based on the theoretical arguments
presented we predict that families with bilineal ADPKD
should exist due to chance in the global population. Be-
cause two disease genes are segregating within the same
family, the probability of disease in the offspring of such
matings will be 75%, rather than 50% as expected for a
dominant trait. The corollary is that ADPKD families with
an increased disease segregation ratio (that is, . 0.5) may
potentially harbor bilineal disease. In such families, inspec-
tion of the PKD1 and PKD2 haplotypes may help to
determine whether the distorted disease segregation ratio
is due to chance or possibly bilineal disease. For example,
five out of the six children in the third generation of the
French Canadian PKD3 family [2] were affected with
ADPKD. Inspection of the PKD1 and PKD2 haplotypes
reveals no sharing of a common haplotype at either of the
known disease gene loci among the affected individuals [2].
Thus, the increased disease segregation ratio (that is,
;0.83) seen in this family could reflect a chance event from
a mutation in a novel gene for ADPKD. Alternatively,
these findings could reflect bilineal disease transmitted
through the affected father (II:3) who would be predicted
to have digenic disease with both a PKD1 and PKD2
mutations. If the latter is correct, the affected father would
have inherited a de novo PKD1 germline mutation from the
unaffected grandfather and a de novo PKD2 germline
mutation from the unaffected grandmother. The gene
products of PKD1 and PKD2 have been recently shown to
interact with each other through a cytoplasmic domain and
are likely involved in a common signaling pathway essential
for normal tubulogenesis [12]. Furthermore, recent studies
have provided evidence suggesting that PKD1 may function
as a “tumor supressor” gene and that cystogenesis in this
form of ADPKD requires the inactivation of both copies of
PKD1 from germline and somatic mutations [13]. Thus, the
identification of patients with two mutations involving
PKD1 and/or PKD2 will be important and may provide a
unique opportunity to further our understanding of the
molecular pathogenesis of ADPKD.
In conclusion, we have provided a review of the common
confounders which could lead to false exclusion of the
putative “PKD3” families from linkage to the known genes
for ADPKD, and suggest that they should be vigorously
excluded. In addition, based on theoretical arguments we
suggest that families with bilineal ADPKD may exist and
may result in apparent exclusion of linkage to the known
genes. With the reagents (that is, polymorphic markers) [9]
and mutation detection systems [10, 11] now available for
the molecular analysis of both PKD1 and PKD2, this
hypothesis can be tested. We suggest that detailed haplo-
type analysis using multiple markers be performed in all
putative “PKD3” families and ADPKD families with in-
creased disease segregation ratios to evaluate the possibil-
ity of bilineal disease. In the same families, we also suggest
screening for mutations in both PKD1 and PKD2 [10, 11].
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Fig. 1. Haplotype of an affected member (III:37) in the Portuguese PKD3
pedigree showing four inter-marker recombinations in the PKD1 region of
the maternal chromosome (Fig. is modified to show only part of the
original pedigree from Fig. 4 in [3]; used with permission from Human
Genetics). The genetic distance between markers 39HVR and SM7 was
estimated from the CEPH v8.1 database (http://www.cephb.fr) using
CRIMAP v2.4. As the female genetic distance between these markers is
only 9.0 cM, it is highly unlikely for four inter-marker recombinations to
occur. Alternative PKD1 haplotypes in this part of the family also require
the same number of recombination events. These findings suggest the
possibility of genotyping error, or DNA sample mix-up. Since III:37 is
affected, non-paternity is considered unlikely. Each X denotes an inter-
marker recombination event.
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